RxDoctor Payments Data

Matthew Nguyen, MD

Cornea and External Diseases Specialist · New York, NYNPI 1235576901

Payments from drug & device makers

What this record shows

This record is dominated by education: $1,200 of the $1,737 with a category attached, or 69.1%. Medwest Associates accounts for 71.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $1,334 and has fallen 91.6% since, to $112 in 2024. That places this record below the midpoint for cornea and external diseases specialist clinicians in NY, where the typical reported total is $2,257.

$1,737in general payments, 2019–2025

Across 20 payments — averaging $86.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medwest Associates$1K
  • Johnson & Johnson$127
  • Alcon$96
  • Novartis$84
  • AbbVie$82
  • Omeros Corporation$37
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$53731%
  • Education$1,20069%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,737 in reported general payments places this provider in the 40th percentile of 26 cornea and external diseases specialist providers in New York.

See all cornea and external diseases specialist providers in New York

Medicare billing

Part B allowed, 2024
$133,629
Medicare patients
416
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine71$78,674
Cyclosporine19$10,201
Prednisolone Acetate101$3,130
MoxifloxacinMoxifloxacin Hcl85$2,030
Ketorolac Tromethamine89$1,520
Azelastine Hcl19$412
Latanoprost44$396
ErythromycinErythromycin Base20$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$82$78,67471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 26 cornea and external diseases specialist providers in New York.

Other cornea and external diseases specialist in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →